drugset / Trial / NCT03657420

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

NCT03657420

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs as a possible treatment for multiple myeloma. The drugs that will be administered are: * ABI-009 (nab-rapamycin) * Pomalidomide * Dexamethasone

Timeline

Start
2019-05-30
Primary completion
2021-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject nab-sirolimus Unknown Intravenous
Background Dexamethasone Small molecule Oral
Background Pomalidomide Other / unclassified Oral

Indications